Physician profile
Malvin S Keller
NPI 1013967520
$2,020.21
in general payments reported to CMS, 2019-2025
21 companies · $403 in 2025
The $403 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $59.13 · 2021: $39.84 · 2022: $148 · 2023: $649 · 2024: $599 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,417 · Travel and Lodging: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,417.21 |
| Travel and Lodging | $233.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $395.18 | 2019-2025 | Wegovy, Ozempic |
| Medtronic, INC. | $347.63 | 2023 | |
| Boston Scientific Corporation | $232.02 | 2019-2024 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Watchman |
| Heartflow, INC. | $223.70 | 2024-2025 | |
| Pfizer INC. | $167.66 | 2019-2025 | |
| Atricure, INC. | $131.14 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Abbott Laboratories | $120.94 | 2019-2023 | Cardiomems, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $57.37 | 2019-2021 | |
| Amgen INC. | $55.28 | 2022-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $53.66 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $42.13 | 2022-2024 | Camzyos |
| Gilead Sciences, INC. | $37.32 | 2019 | |
| Biosense Webster, INC. | $30.20 | 2020 | |
| Cvrx, INC. | $19.23 | 2025 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $17.34 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $17.00 | 2024 | Tyvaso |
| Daiichi Sankyo INC. | $16.15 | 2023 | Injectafer |
| Scpharmaceuticals INC. | $14.67 | 2024 | |
| Sanofi Pasteur INC. | $14.29 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.78 | 2023 | |
| Acarix USA INC. | $13.52 | 2023 | Cadscor System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malvin Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.